Current Neuro-Oncology
Volume
26 Number 20
20 September 2024
Home > Publications > Current Neuro-Oncology > Volume 26, Year 2024 > Number 20, 20 September
Lim-Fat MJ, Wen PY, Touat M, Puduvalli VK, Iorgulescu JB.
MGMT
promoter methylation and survival following chemotherapy for WHO
grade 4 IDH-mutant astrocytoma.
Neuro
Oncol. 2024 Sep 11:noae157. doi:
10.1093/neuonc/noae157. PMID:
39277807. Observational study˰
ˍ
Mareček D, Kopecká V, Matěj R, Strýček
O.
Bilateral thalamic glioblastoma
presenting as parkinsonism: A case report.
Parkinsonism
Relat Disord. 2024 Sep 11;128:107147. doi:
10.1016/j.parkreldis.2024.107147. PMID:
39276721. Case report˰
ˍ
Hu G, Tian B, Han S, Wang S, Hacker M, Li X, Bai X.
Prognostic
evaluation in recurrent glioma through 11C-Choline
PET/CT imaging.
EJNMMI
Res. 2024 Sep 12;14(1):84. doi:
10.1186/s13550-024-01146-x. PMID:
39266803. Observational study. ˍ
Rixe O, Villano JL, Wesolowski R, Noonan AM, Puduvalli VK,
Wise-Draper TM, Curry R, Yilmaz E, Cruze C, Ogretmen B, Tapolsky
G, Takigiku R.
A first-in-human phase
1 study of BXQ-350, a first-in-class sphingolipid metabolism
regulator, in patients with advanced/recurrent solid tumors or
high-grade gliomas.
Clin
Cancer Res. 2024 Sep 12. doi:
10.1158/1078-0432.CCR-24-1721. PMID:
39264252. Interventional study˰
ˍ
*Sloan L, Sen R, Liu C, Doucet M, Blosser L, Katulis L, Kamson DO,
Grossman S, Holdhoff M, Redmond KJ, Quon H, Lim M, Eberhart C,
Pardoll DM, Hu C, Ganguly S, Kleinberg LR.
Radiation
immunodynamics in patients with glioblastoma receiving
chemoradiation.
Front
Immunol. 2024 Sep 13;15:1438044. doi:
10.3389/fimmu.2024.1438044. PMID:
39346903. Observational study. ˍ
Sun Z, Feng D, Zhu R.
A case of adult
medulloblastoma.
Asian J Surg. 2024 Sep
13:S1015-9584(24)01979-1. doi:
10.1016/j.asjsur.2024.08.239. PMID:
39271311. Case report. ˍ
Limon D, Amiel A, Even Haim S, Gordon N, Tschernichovsky R,
Stemmer S, Gal O, Laviv Y, Kanner A, Siegal T, Yust-Katz S.
A
phase II, open-label, single-arm trial of pembrolizumab for
recurrent meningioma and solitary fibrous tumor.
Neurooncol
Adv. 2024 Sep 16;6(1):vdae154. doi:
10.1093/noajnl/vdae154. PMID:
39429970. Interventional study. ˍ
Reimann RR, Gramatzki D, Bink A, Hench J, Frank S, Haberecker M,
Hortobagyi T, Egervari K, Merkler D, Aldape K, Weller M.
Long
survival in a patient with fumarate hydratase mutation-associated
glioma.
J
Neuropathol Exp Neurol. 2024 Sep 16:nlae100. doi:
10.1093/jnen/nlae100. PMID:
39279228. Case report. ˍ
Hickman RA, Miller AM, Holle BM, Jee J, Liu SY, Ross D, Yu H,
Riely GJ, Ombres C, Gewirtz AN, Reiner AS, Nandakumar S, Price A,
Kaley TJ, Graham MS, Vanderbilt C, Rana S, Hill K, Chabot K,
Campos C, Nafa K, Shukla N, Karajannis M, Li B, Berger M, Ladanyi
M, Pentsova E, Boire A, Brannon AR, Bale T, Mellinghoff IK, Arcila
ME.
Real-world experience with
circulating tumor DNA in cerebrospinal fluid from patients with
central nervous system tumors.
Acta
Neuropathol Commun. 2024 Sep 17;12(1):151. doi:
10.1186/s40478-024-01846-4. PMID:
39289779. Observational study. ˍ
Sekino Y, Sonoda Y, Shibahara I, Mizusawa J, Sasaki K, Sekita T,
Ichikawa M, Igaki H, Kinoshita M, Kumabe T, Shibahara J, Ichimura
K, Arakawa Y, Fukuda H; Brain Tumor Study Group (BTSG) of the
Japan Clinical Oncology Group (JCOG); Narita Y.
Protocol
digest of a phase III randomized trial of gross total resection
versus possible resection of fluid-attenuated inversion
recovery-hyperintense lesion on MRI for newly diagnosed
supratentorial glioblastoma: JCOG2209 (FLAMINGO).
Jpn
J Clin Oncol. 2024 Sep 17:hyae130. doi:
10.1093/jjco/hyae130. PMID:
39292165. Interventional study protocol˰
ˍ
Laetsch TW, Ludwig K, Williams PM, Roy-Chowdhuri S, Patton DR,
Coffey B, Reid JM, Piao J, Saguilig L, Alonzo TA, Berg SL, Mhlanga
J, Fox E, Weigel BJ, Hawkins DS, Mooney MM, Takebe N, Tricoli JV,
Janeway KA, Seibel NL, Parsons DW.
Phase
II Study of Samotolisib in Children and Young Adults With Tumors
Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin
Pathway Alterations: Pediatric MATCH APEC1621D.
JCO
Precis Oncol. 2024 Sep 19;8:e2400258. doi:
10.1200/PO.24.00258. PMID:
39298693. Interventional study˰
ˍ
*An S, Lin H, Zhang Y, Pang B, Yan H, Liu Y, Wang L, Wu Y, Chai R,
Jia W, Wang Y.
Central nervous system
dissemination in spinal cord astrocytomas: association with H3
K27M mutation.
J
Neurosurg Spine. 2024 Sep 20:1-10. doi:
10.3171/2024.6.SPINE24233. PMID:
39303298. Observational study. ˍ
Ng S, Rigau V, Moritz-Gasser S, Gozé C, Darlix A, Herbet G,
Duffau H.
Long-term autonomy,
professional activities, cognition, and overall survival after
awake functional-based surgery in patients with IDH-mutant grade 2
gliomas: a retrospective cohort study.
Lancet
Reg Health Eur. 2024 Sep 20;46:101078. doi:
10.1016/j.lanepe.2024.101078. PMID:
39381547. Observational study. ˍ
Shigekawa S, Inoue A, Endo T, Muto J, Inoue T, Kanematsu R,
Mitsuhara T, Umebayashi D, Mizuno M, Hida K, Kunieda T;
Investigators of Intramedullary Spinal Cord Tumors in the
Neurospinal Society of Japan.
Optimal
treatment strategy for low-grade spinal cord astrocytoma: a
retrospective, multicenter analysis by the Neurospinal Society of
Japan.
J
Neurosurg Spine. 2024 Sep 20:1-9. doi:
10.3171/2024.5.SPINE24457. PMID:
39303310. Observational study˰
ˍ